a. Data shown are an aggregate of all your provider locations.
b. The comparator group ‘RA’ includes all general practitioners currently located in a similar geographical location (ie, 1. major city, 2. inner regional, 3. outer regional, 4. remote, 5. very remote).
c. Aggregate MedicineInsight data on 1 August 2017
d. Includes ezetimibe products with an approved indication for statin-related clinically important adverse events as per the following authority codes: 5562/3731 (ezetimibe 10 mg); 4353 (atorvastatin 10 mg + ezetimibe 10 mg); 4147 (rosuvastatin 10 mg + ezetimibe 10 mg; simvastatin 10 mg + ezetimibe 10 mg; simvastatin 20 mg + ezetimibe 10 mg).
e. According to PBS criteria, clinically important adverse event is defined as severe myalgia (muscle symptoms without creatine kinase elevation); myositis (clinically important creatine kinase elevation with or without muscle symptoms) or unexplained, persistent elevations of serum transaminases during statin treatment.